Trial Profile

A Single-arm, Multi-center Exploratory Clinical Study of Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2024 Results(From Mar 2022 to Sep 2022,n=46) investigating the efficacy and safety of anlotinib plus TQB2450 as first-line therapy , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Oct 2023 Updated Results investigating the efficacy and safety of anlotinib plus TQB2450 as first-line therapy for patients with advanced ESCC, presented at the 48th European Society for Medical Oncology Congress
06 Jun 2023 Preliminary results (At the data cut-off date , Dec, 2022) presented at the 59th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com